Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5823199 | 0.78 | — | — | |
| SCHEMBL2526766 | 0.77 | TSHR (0.34) | TSHR | |
| SCHEMBL3503384 | 0.76 | — | — | |
| SCHEMBL6891504 | 0.75 | TDP1 (0.35) | TSHR | |
| SCHEMBL602024 | 0.75 | TDP1 (0.35) | TSHR | |
| Hydrochloric Acid SCHEMBL28583405 | 0.75 | — | — | |
| Sulfuric Acid SCHEMBL28661430 | 0.70 | NLRP3 (0.36) | — | |
| SCHEMBL7107508 | 0.69 | TSHR (0.32) | TSHR | |
| SCHEMBL8740079 | 0.67 | — | — | |
| SCHEMBL13493927 | 0.67 | TSHR (0.33) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6921818-B2 | Purification of oligomers | YALE UNIVERSITY (US) | 2005-07-26 | — | — | US | claimed |
| US-6620926-B2 | Composition for use in the generation and purification of oligonucleotide sequences | YALE UNIVERSITY | 2003-09-16 | — | — | US | claimed |
| US-20250243250-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIV AUTÒNOMA DE BARCELONA UAB (ES) | 2025-07-31 | — | — | US | disclosed |
| US-20250215040-A1 | METHOD AND COMPOUND | ATDBio Limited (GB) | 2025-07-03 | — | — | US | disclosed |
| US-20250042932-A1 | METHOD FOR PRODUCING POLYNUCLEOTIDES | ATDBio Limited (GB) | 2025-02-06 | — | — | US | disclosed |
| US-12202866-B2 | Therapeutic nanoconjugates and uses thereof | UNIVERSITAT AUTONOMA DE BARCELONA (UAB) (ES) | 2025-01-21 | — | — | US | disclosed |
| EP-4249495-A1 | METHOD FOR THE PURIFICATION OF POLYNUCLEOTIDES AND ANALOGUES THEREOF | ATDBio Limited (GB) | 2023-09-27 | — | — | EP | disclosed |
| EP-4186914-A1 | METHOD FOR PRODUCING POLYNUCLEOTIDES | ATDBio Limited (GB) | 2023-05-31 | — | — | EP | disclosed |
| US-20200223893-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | CONSORCIO CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED (ES) | 2020-07-16 | — | — | US | disclosed |
| EP-3651809-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | Universitat Autónoma De Barcelona (UAB) (ES) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012157-A1 | THERAPEUTIC NANOCONJUGATES AND USES THEREOF | UNIVERSITAT AUTÒNOMA DE BARCELONA (UAB) (ES) | 2019-01-17 | — | — | WO | disclosed |
| US-5367066-A | Oligonucleotides with selectably cleavable and/or abasic sites | CHIRON CORPORATION (US) | 1994-11-22 | — | — | US | disclosed |
| WO-1994015620-A1 | NOVEL OLIGONUCLEOTIDES MODIFIED WITH NON-NUCLEOTIDE BRIDGING GROUPS | PHARMAGENICS, INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| EP-0543889-A4 | INCORPORATION OF SELECTABLY CLEVABLE AND/OR ABASIC SITES INTO OLIGONUCLEOTIDE CHAINS AND REAGENTS THEREFOR | CHIRON CORP (US) | 1994-05-18 | — | — | EP | disclosed |
| EP-0547008-A1 | New antisense oligonucleotides | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 1993-06-16 | — | — | EP | disclosed |
| EP-0504278-A4 | A NEW METHOD FOR DETECTING A SPECIFIC NUCLEIC ACID SEQUENCE IN A SAMPLE OF CELLS | — | 1993-06-09 | — | — | EP | disclosed |
| EP-0543889-A1 | INCORPORATION OF SELECTABLY CLEVABLE AND/OR ABASIC SITES INTO OLIGONUCLEOTIDE CHAINS AND REAGENTS THEREFOR | CHIRON CORPORATION (US) | 1993-06-02 | — | — | EP | disclosed |
| EP-0504278-A1 | A NEW METHOD FOR DETECTING A SPECIFIC NUCLEIC ACID SEQUENCE IN A SAMPLE OF CELLS. | PHARMACIA GENETIC ENG (US) | 1992-09-23 | — | — | EP | disclosed |
| WO-1992002528-A1 | INCORPORATION OF SELECTABLY CLEVABLE AND/OR ABASIC SITES INTO OLIGONUCLEOTIDE CHAINS AND REAGENTS THEREFOR | CHIRON CORPORATION (US) | 1992-02-20 | — | — | WO | disclosed |
| WO-1991008308-A1 | A NEW METHOD FOR DETECTING A SPECIFIC NUCLEIC ACID SEQUENCE IN A SAMPLE OF CELLS | PHARMACIA GENETIC ENGINEERING, INC. (US) | 1991-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042932-A1 | METHOD FOR PRODUCING POLYNUCLEOTIDES | POLN, RNGTT, PNP | TSHR 3858/4885 |
| US-20250215040-A1 | METHOD AND COMPOUND | POLN, POLRMT, FBL | TSHR 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.